INTS Clinical Study Reveals High Disease Control and Survival Benefits for Advanced Cancers
Intensity Therapeutics, Inc. (NASDAQ: INTS) made waves today as it announced the publication of its phase 1/2 clinical results for INT230-6 in eBioMedicine, a journal in The Lancet Discovery Science group. The study delivers a comprehensive look at efficacy and safety in heavily pretreated patients with metastatic or refractory solid tumors, revealing strong potential for this investigational therapy across more than 20 different cancer types.
High Disease Control and Extended Survival in Tough-to-Treat Patients
What stands out in this new publication is the substantial disease control rate and median overall survival achieved. Among 64 patients who had progressed through multiple lines of prior therapy, INT230-6 delivered:
| Key Metric | INT230-6 Result | Historical Reference (Phase 1/2) |
|---|---|---|
| Disease Control Rate | 75.0% (48/64) | - |
| Median Overall Survival (mOS) | 11.9 months | 4 – 7 months |
| Sarcoma Subset (mOS) | 21.3 months | - |
For context, historical phase 1/2 studies in similarly advanced cancer populations reported a median survival of just 4 to 7 months. In the sarcoma subset, patients saw a remarkable mOS of 21.3 months.
Dose Volume Matters: Higher Doses Drive Even Stronger Results
In an exploratory analysis, outcomes were compared by dose intensity. Patients receiving INT230-6 at a dose treating over 40% of total tumor burden (TTB) fared even better:
| Dose Group | Disease Control Rate | Median OS | Hazard Ratio (95% CI) |
|---|---|---|---|
| >40% TTB | 83.3% (40/48) | 18.7 months | 0.17 (0.081–0.34) |
| <40% TTB | 50.0% (8/16) | 3.1 months | - |
This improvement held up regardless of baseline tumor size, indicating a direct relationship between INT230-6 dosing strategy and patient outcomes. The data also point to at least 20% of higher-dose patients experiencing the so-called “abscopal effect,” where uninjected tumors shrink—a rare and notable phenomenon in local therapies.
Favorable Safety Profile Even at High Dose Volumes
The study further found that over 95% of the drug’s cytotoxic agents stayed confined within injected tumors, supporting both local action and minimized systemic exposure. Among the 64 monotherapy patients, no dose-limiting toxicities were reported, with just 10.9% experiencing grade 3 adverse events and no grade 4 or 5 treatment-related adverse events observed.
Evidence of Systemic Immune Activation Supports Broader Therapeutic Potential
Biopsy analysis revealed an uptick in activated T-cell infiltration into tumors after INT230-6 injection, aligning with preclinical findings of immune system engagement. These results suggest the potential for INT230-6 not only to directly destroy injected tumors but also to stimulate a broader anti-cancer immune response—even in cancer types that are considered immunologically 'cold.'
Looking Ahead: Ongoing Studies and Broader Applications
With the positive clinical and safety profile shown, Intensity Therapeutics is now advancing randomized phase 3 studies in sarcoma and ongoing phase 2 trials in breast cancer. The company’s strategy hinges on leveraging its proprietary DfuseRx™ technology to transform deadly metastatic cancers into chronic conditions—and potentially alter standard cancer care paradigms.
Takeaway for Investors and Clinicians
The results published in eBioMedicine suggest INT230-6 may offer a new avenue for patients who have exhausted standard therapies. A high disease control rate, impressive survival benefits—especially at higher dose intensities—and a favorable safety profile collectively position INT230-6 as a candidate worth watching as further late-stage data readouts emerge. The full study is now open access, and a dedicated webinar with key authors is scheduled for October 31, 2025.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI